Figure 7

AZD7762 enhanced TH-302 efficacy in HT29 xenograft. Antitumor efficacy of TH-302 alone or in combination with AZD7762 under TH-302 Intermittent Dosing Regimen, presented as study design (A), tumor growth curve (B, E), Kaplan-Meier plot (C, F) and body weight change (D, G); TH-302 was given ip at 100 mg/kg, twice a week and AZD7762 was given at 20 (B, C, and D) and 12.5 mg/kg (E, F and G), four times a week, respectively. Two dosing sequences, ATA and TAA, were employed in the combination groups. Antitumor efficacy of TH-302 alone or in combination with AZD7762 under TH-302 Daily Dosing Regimen, presented as study design (H), tumor growth curve (I), Kaplan-Meier plot (J) and body weight change (K). TH-302 and AZD7762 were given ip daily for 5 days a week at 50 and 12.5 mg/kg, respectively. In the combination group, TH-302 was given 4 hours prior to AZD7762. Data are mean ± SEM of 10 animals per group.